Literature DB >> 30958547

Early Clearance of Mycobacterium tuberculosis Is Associated With Increased Innate Immune Responses.

Ayesha J Verrall1, Marion Schneider2, Bachti Alisjahbana3,4, Lika Apriani3,5, Arjan van Laarhoven6, Valerie A C M Koeken6, Suszanne van Dorp7, Emira Diadani3, Fitri Utama3, Rachel F Hannaway2, Agnes Indrati8, Mihai G Netea6,9, Katrina Sharples10, Philip C Hill11, James E Ussher2, Reinout van Crevel6.   

Abstract

BACKGROUND: A proportion of tuberculosis (TB) case contacts do not become infected, even when heavily exposed. We studied the innate immune responses of TB case contacts to understand their role in protection against infection with Mycobacterium tuberculosis, termed "early clearance."
METHODS: Indonesian household contacts of TB cases were tested for interferon-γ release assay (IGRA) conversion between baseline and 14 weeks post recruitment. Blood cell populations and ex vivo innate whole blood cytokine responses were measured at baseline and, in a subgroup, flow cytometry was performed at weeks 2 and 14. Immunological characteristics were measured for early clearers, defined as a persistently negative IGRA at 3 months, and converters, whose IGRA converted from negative to positive.
RESULTS: Among 1347 case contacts, 317 were early clearers and 116 were converters. Flow cytometry showed a resolving innate cellular response from 2 to 14 weeks in persistently IGRA-negative contacts but not converters. There were no differences in cytokine responses to mycobacterial stimuli, but compared to converters, persistently IGRA-negative contacts produced more proinflammatory cytokines following heterologous stimulation with Escherichia coli and Streptococcus pneumoniae.
CONCLUSIONS: Early clearance of M. tuberculosis is associated with enhanced heterologous innate immune responses similar to those activated during induction of trained immunity.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Mycobacteriumzzm321990 ; zzm321990 tuberculosis infection; BCG vaccine; early clearance; monocytes; trained innate immunity

Mesh:

Year:  2020        PMID: 30958547     DOI: 10.1093/infdis/jiz147

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Targeting innate immunity for tuberculosis vaccination.

Authors:  Shabaana A Khader; Maziar Divangahi; Willem Hanekom; Philip C Hill; Markus Maeurer; Karen W Makar; Katrin D Mayer-Barber; Musa M Mhlanga; Elisa Nemes; Larry S Schlesinger; Reinout van Crevel; Raman (Krishna) Vankayalapati; Ramnik J Xavier; Mihai G Netea
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

2.  Mesenchymal-epithelial Transition Factor Regulates Monocyte Function during Mycobacterial Infection via Indoleamine 2,3-dioxygenase.

Authors:  Bing-Fen Yang; Fei Zhai; Hong-Juan An; Jing Jiang; Zhi-Hong Cao; Yan-Hua Liu; Jin-Wen Su; Ruo Wang; Xiao-Xing Cheng
Journal:  Curr Med Sci       Date:  2022-03-02

Review 3.  Macrophage: A Cell With Many Faces and Functions in Tuberculosis.

Authors:  Faraz Ahmad; Anshu Rani; Anwar Alam; Sheeba Zarin; Saurabh Pandey; Hina Singh; Seyed Ehtesham Hasnain; Nasreen Zafar Ehtesham
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

4.  Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study.

Authors:  Davit Baliashvili; Neel R Gandhi; Soyeon Kim; Michael Hughes; Vidya Mave; Alberto Mendoza-Ticona; Pedro Gonzales; Kim Narunsky; Poongulali Selvamuthu; Sharlaa Badal-Faesen; Caryn Upton; Linda Naini; Elizabeth Smith; Amita Gupta; Gavin Churchyard; Susan Swindells; Anneke Hesseling; N Sarita Shah
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

Review 5.  The knowns and unknowns of latent Mycobacterium tuberculosis infection.

Authors:  W Henry Boom; Ulrich E Schaible; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

6.  Changes in Transcript, Metabolite, and Antibody Reactivity During the Early Protective Immune Response in Humans to Mycobacterium tuberculosis Infection.

Authors:  January Weiner; Teresa Domaszewska; Simon Donkor; Stefan H E Kaufmann; Philip C Hill; Jayne S Sutherland
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

7.  Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.

Authors:  Robert J Blount; Ha Phan; Trang Trinh; Hai Dang; Cindy Merrifield; Michael Zavala; Joseph Zabner; Alejandro P Comellas; Emma M Stapleton; Mark R Segal; John Balmes; Nguyen Viet Nhung; Payam Nahid
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

8.  Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion.

Authors:  Jason D Simmons; Phu T Van; Catherine M Stein; Violet Chihota; Thobani Ntshiqa; Pholo Maenetje; Glenna J Peterson; Anthony Reynolds; Penelope Benchek; Kavindhran Velen; Katherine L Fielding; Alison D Grant; Andrew D Graustein; Felicia K Nguyen; Chetan Seshadri; Raphael Gottardo; Harriet Mayanja-Kizza; Robert S Wallis; Gavin Churchyard; W Henry Boom; Thomas R Hawn
Journal:  J Clin Invest       Date:  2021-07-15       Impact factor: 19.456

Review 9.  Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.

Authors:  Elisa Nemes; Shabaana A Khader; Rosemary V Swanson; Willem A Hanekom
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561

10.  The effect of BCG vaccination on alveolar macrophages obtained from induced sputum from healthy volunteers.

Authors:  Valerie A C M Koeken; Eva S van der Pasch; Guus P Leijte; Vera P Mourits; L Charlotte J de Bree; Simone J C F M Moorlag; Isadore Budnick; Nina Idh; Maria Lerm; Matthijs Kox; Arjan van Laarhoven; Mihai G Netea; Reinout van Crevel
Journal:  Cytokine       Date:  2020-06-10       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.